Clinical trials: Liver Tumour
Advanced Solid Tumors With and Without Brain Metastases
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases).
- Trial name
- NCT00539383
- Testing
- ANG1005
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Angiochem Inc
Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced…
- Trial name
- NCT07490262
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Hepatocellular Carcinoma
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC)…
- Trial name
- Kirros (NCT06096779)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced…
- Trial name
- PHOCUS (NCT02562755)
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
- Where
- 142 sites in United States, Australia and 14 more
- Volunteers
- 459 people
- Sponsor
- SillaJen, Inc.
Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer.
- Conditions
- Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
- Trial name
- NCT02174549
- Testing
- Tirapazamine, Conventional Transarterial Embolization (TAE)
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Teclison Ltd.
Carcinoma, Hepatocellular
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat with sorafenib has not been made…
- Trial name
- NCT01191385
- Testing
- Any treatment for unresectable HCC as chosen by the physician
- Where
- 24 sites in United States
- Sponsor
- Bayer
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Solid Tumor, Hepatocellular Carcinoma
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC
- Trial name
- NCT04780217
- Testing
- T3011
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- ImmVira Pharma Co. Ltd
Hepatic Impairment, Advanced Malignant Solid Tumor
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe…
- Trial name
- NCT04241835
- Testing
- Tazemetostat
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Liver Diseases, Digestive System Diseases
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
This is a Phase 1, multicenter, nonrandomized, open-label, parallel-group study in participants with mild or moderate hepatic impairment, and in participants with normal hepatic function.
- Trial name
- NCT04639115
- Testing
- Ozanimod
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
Liver Cancer
DX-8951f in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
- Trial name
- NCT00004108
- Testing
- exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Solid Tumors, Non-small Cell Lung Cancer
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors.
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05024214
- Testing
- Lenvatinib + Envafolimab, Sunitinib
- Where
- 23 sites in China
- Volunteers
- 170 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Advanced Hepatocellular Carcinoma (HCC)
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects…
- Trial name
- NCT04212221
- Testing
- MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Carcinoma, Hepatocellular
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Primary: To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin Secondary: Safety and tolerability of this regimen in these…
- Trial name
- NCT00280618
- Testing
- Oxaliplatin
- Sponsor
- Sanofi
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Carcinoma, Hepatocellular
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes.
- Trial name
- SHARP (NCT00105443)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 178 sites in United States, Argentina and 21 more
- Volunteers
- 602 people
- Sponsor
- Bayer
Tumor, Solid, Tumor
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
- Conditions
- Tumor, Solid, Tumor, Advanced Solid Tumor
- Trial name
- NCT05661461
- Testing
- nab-sirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Lung Cancer, Liver Cancer
Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy
This is a feasibility study investigating the image quality of a new, high-performance cone beam CT (CBCT) used for on-couch imaging during radiotherapy treatments.
- Conditions
- Lung Cancer, Liver Cancer, Breast Cancer, Other Cancer
- Trial name
- NCT05176860
- Testing
- CBCT Imaging
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Varian, a Siemens Healthineers Company
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC